Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
Indexed incrossrefpubmed
Abstract
A patient with refractory multiple myeloma received an infusion of CTL019 cells, a cellular therapy consisting of autologous T cells transduced with an anti-CD19 chimeric antigen receptor, after myeloablative chemotherapy (melphalan, 140 mg per square meter of body-surface area) and autologous stem-cell transplantation. Four years earlier, autologous transplantation with a higher melphalan dose (200 mg per square meter) had induced only a partial, transient response. Autologous transplantation followed by treatment with CTL019 cells led to a complete response with no evidence of progression and no measurable serum or urine monoclonal protein at the most recent evaluation, 12 months after treatment. This…
Citation impact
635
total citations
- FWCI
- 36.08
- Percentile
- 100%
- References
- 19
Citations per year
Authors
16Topics & keywords
Topics
Keywords
- Melphalan
- Medicine
- Multiple myeloma
- Chimeric antigen receptor
- Autologous stem-cell transplantation
- Transplantation
- CD19
- Stem cell
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.